AUTHORS
Ibtida Tabassum Ishmam, MS, Cody William Carter, BS, MS2, Michael Poulos, PhD3, Pradeep Ramalingam, MD PhD4, Jason Butler, Ph.D.5
AFFILIATIONS
1 University of Florida, Gainesville, Florida, United States
2 University of Florida, Gainesville, Florida, United States
3 University of Florida, Gainesville, Florida, United States
4 University of Florida, Gainesville, Florida, United States
5 University of Florida, Gainesville, Florida, United States
ABSTRACT
The hematopoietic system is maintained by hematopoietic stem cells (HSCs), which reside within the specialized bone marrow (BM) microenvironment. Within this microenvironment, the BM vascular niche, particularly bone marrow endothelial cells (BMECs), serve as a critical regulator of HSC maintenance and function. However, aging induces profound alterations in the BM vascular niche that impair endothelial cell function, including loss of stress response, repair, and angiogenic programs, reduced proliferative capacity, and impaired activation of transcriptional factors. Moreover, age-related BMEC dysfunction leads to a diminished capacity to serve as an HSC-supportive niche, contributing to hematopoietic decline and reduced regenerative capacity. Additionally, disruption in BMEC function increases susceptibility to hematologic disease and impairs tolerance to myeloablative therapies. The molecular mechanisms underlying vascular niche aging and whether niche rejuvenation can restore hematopoietic fitness remain incompletely understood.
Our previous studies demonstrate that BMECs are critical determinants of HSC function and that aging of BMECs dictates their instructive capacity. We have shown that young BMECs support regenerative HSC properties, whereas aged BMECs impair HSC self-renewal and engraftment. Building upon this prior work, we investigated the molecular mechanisms underlying vascular niche aging. Transcriptomic and proteomic analyses identified increased expression of fibrinogen-like protein 2 (Fgl2) and its receptor FcγRIIB (Fcgr2b) in aged BMECs, indicating activation of the Fgl2/Fcgr2b signaling axis during vascular aging. To further confirm that Fcgr2b was expressed on BMECs and that its expression is increased during aging, we intravitally labeled the vasculature of young (3 months) and aged (18 months) mice by intravenously infusing anti-Fcgr2b antibody conjugated to Alexa-647. Quantification of Fcgr2b by flow cytometry revealed a ~4-fold increase in Fcgr2b on aged endothelium, confirming our proteomics data. We next sought to determine if the Fgl2/Fcgr2b signaling axis could affect hematopoietic parameters in young mice. We observed that infusion of recombinant Fgl2 (rFgl2) resulted in significant decreases in complete blood counts while causing an increase in the frequency of phenotypic HSCs. Based on this data, we set out to determine how infusion of rFgl2 impacts the BM vascular niche and hematopoietic function. To this end, we performed competitive whole BM transplants and found that young mice treated with rFgl2 had significantly lower long-term engraftment, despite an increase in phenotypic HSC, as well as a myeloid bias at the expense of lymphopoiesis, hallmark features of an aged HSC. Additionally, treatment with rFgl2 resulted in a vascular system that was substantially disrupted and significantly leakier, similar to aged controls. This data demonstrates that exogenous infusion of rFgl2 in young mice leads to phenotypic changes to the hematopoietic system and disrupts the function of the BM vascular system.
To determine the functional role of vascular Fcgr2b signaling in hematopoietic fitness, we generated a novel animal model in which we deleted Fcgr2b specifically in ECs (CDH5-FCGR2B mice). CDH5-FCGR2B mice exhibited normal steady-state hematopoiesis. However, following a competitive HSC transplant, we found that HSCs isolated from CDH5-FCGR2B mice demonstrated more than a four-fold increase in donor-derived engraftment. Additionally, CDH5-FCGR2B mice showed accelerated hematopoietic recovery following myelosuppressive stress compared with controls. To further assess long-term HSC regenerative capacity, we subjected mice to serial myelosuppression; following four rounds of irradiation, CDH5-FCGR2B mice exhibited substantially greater survival (60%) than control mice (<10%). Together, these findings indicate that endothelial-specific deletion of Fcgr2b enhances HSC function both at steady state and during hematopoietic regeneration. Together, these findings demonstrate that inhibiting vascular Fcgr2b signaling enhances hematopoietic function and may serve as a therapeutic to preserve and/or rejuvenate aged vascular and HSC function.
DISCLOSURES
Ibtida Tabassum Ishmam, MS: No relevant conflicts of interest to declare.